Two years ago, Hua Medicine turned to the public markets to help finance its ambitious diabetes program. “Our future success depends substantially on the success in China of our only clinical drug candidate, dorzagliatin,” the Shanghai-based pharma said in its IPO filing.
The company kept plugging away at the effort quietly until last week, when it announced the completion of its first Phase 3 trial. A positive readout sent the stock soaring 27% — and could make Hua the first company globally to win approval for a novel diabetes therapy known as a glucokinase activator, a class also being developed in the United States, India, and Japan.
Continue to STAT Plus to read the full story…
Anupam Ghose, a physician by training, was diagnosed with Type 2 Diabetes Mellitus (T2DM) in 2017. After the diagnosis of T2DM, he followed a low carbohydrate high fat diet and reversed his T2DM within a year. Now he has one main goal in life and that is to make people understand that the conventional method of treating T2DM is not beneficial. Type 2 diabetes is reversible and the best way to reverse T2DM is through diet and lifestyle modifications. He now decided to help people with type 2 diabetes by offering online coaching to reverse their diabetes.
